Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome

M. L. Markel, E. N. Prystowsky, J. J. Heger, W. M. Miles, N. Fineberg, D. P. Zipes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Encainide is a newly released type Ic antiarrhythmic agent which, when taken orally, prolongs AV nodal conduction time, His-Purkinje conduction time, and refractoriness in the atrium, ventricle, and accessory pathways. Thirty-three patients with drug resistant supraventricular tachycardias associated with WPW were treated with oral encainide ranging from 100 mg to 300 mg daily (mean 187 mg) with EPS performed pre- and post-drug treatment. Long-term follow-up (mean 26.4 months) revealed overall favorable response to therapy in 24/33 patients (73%). Side effects were not significant. Encainide appears to be an effective drug for these patients.

Original languageEnglish (US)
Pages (from-to)261-265
Number of pages5
JournalJournal of Electrophysiology
Volume1
Issue number3
StatePublished - Jan 1 1987

Fingerprint

Encainide
Wolff-Parkinson-White Syndrome
Supraventricular Tachycardia
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Markel, M. L., Prystowsky, E. N., Heger, J. J., Miles, W. M., Fineberg, N., & Zipes, D. P. (1987). Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. Journal of Electrophysiology, 1(3), 261-265.

Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. / Markel, M. L.; Prystowsky, E. N.; Heger, J. J.; Miles, W. M.; Fineberg, N.; Zipes, D. P.

In: Journal of Electrophysiology, Vol. 1, No. 3, 01.01.1987, p. 261-265.

Research output: Contribution to journalArticle

Markel, ML, Prystowsky, EN, Heger, JJ, Miles, WM, Fineberg, N & Zipes, DP 1987, 'Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome', Journal of Electrophysiology, vol. 1, no. 3, pp. 261-265.
Markel ML, Prystowsky EN, Heger JJ, Miles WM, Fineberg N, Zipes DP. Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. Journal of Electrophysiology. 1987 Jan 1;1(3):261-265.
Markel, M. L. ; Prystowsky, E. N. ; Heger, J. J. ; Miles, W. M. ; Fineberg, N. ; Zipes, D. P. / Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. In: Journal of Electrophysiology. 1987 ; Vol. 1, No. 3. pp. 261-265.
@article{a029692e83cb4415adcbf2f0fcf94f30,
title = "Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome",
abstract = "Encainide is a newly released type Ic antiarrhythmic agent which, when taken orally, prolongs AV nodal conduction time, His-Purkinje conduction time, and refractoriness in the atrium, ventricle, and accessory pathways. Thirty-three patients with drug resistant supraventricular tachycardias associated with WPW were treated with oral encainide ranging from 100 mg to 300 mg daily (mean 187 mg) with EPS performed pre- and post-drug treatment. Long-term follow-up (mean 26.4 months) revealed overall favorable response to therapy in 24/33 patients (73{\%}). Side effects were not significant. Encainide appears to be an effective drug for these patients.",
author = "Markel, {M. L.} and Prystowsky, {E. N.} and Heger, {J. J.} and Miles, {W. M.} and N. Fineberg and Zipes, {D. P.}",
year = "1987",
month = "1",
day = "1",
language = "English (US)",
volume = "1",
pages = "261--265",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Encainide for the treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome

AU - Markel, M. L.

AU - Prystowsky, E. N.

AU - Heger, J. J.

AU - Miles, W. M.

AU - Fineberg, N.

AU - Zipes, D. P.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Encainide is a newly released type Ic antiarrhythmic agent which, when taken orally, prolongs AV nodal conduction time, His-Purkinje conduction time, and refractoriness in the atrium, ventricle, and accessory pathways. Thirty-three patients with drug resistant supraventricular tachycardias associated with WPW were treated with oral encainide ranging from 100 mg to 300 mg daily (mean 187 mg) with EPS performed pre- and post-drug treatment. Long-term follow-up (mean 26.4 months) revealed overall favorable response to therapy in 24/33 patients (73%). Side effects were not significant. Encainide appears to be an effective drug for these patients.

AB - Encainide is a newly released type Ic antiarrhythmic agent which, when taken orally, prolongs AV nodal conduction time, His-Purkinje conduction time, and refractoriness in the atrium, ventricle, and accessory pathways. Thirty-three patients with drug resistant supraventricular tachycardias associated with WPW were treated with oral encainide ranging from 100 mg to 300 mg daily (mean 187 mg) with EPS performed pre- and post-drug treatment. Long-term follow-up (mean 26.4 months) revealed overall favorable response to therapy in 24/33 patients (73%). Side effects were not significant. Encainide appears to be an effective drug for these patients.

UR - http://www.scopus.com/inward/record.url?scp=0023510789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023510789&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023510789

VL - 1

SP - 261

EP - 265

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 3

ER -